<< Studies demonstrate that investigational cancer vaccines show encouraging immune response rates | MasterControl and i4DM to implement a quality management system for the U.S. FDA >>

Read in | English | Español | 한국어 | Filipino

Shire's ADHD treatment data to be presented at the Honolulu psychiatric meeting

Published on October 30, 2009 at 6:01 AM · No Comments

Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV(TM) (guanfacine) Extended Release Tablets, Vyvanse®( ) (lisdexamfetamine dimesylate) Capsules CII, and Daytrana®( ) (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.

"Shire is committed to the advancement of ADHD treatment research and is leading the way in developing a diverse range of safe and effective ADHD treatments," said Michael Yasick, Senior Vice President of the Shire ADHD Business Unit. "We are excited to provide new scientific data on our ADHD portfolio, which includes the newest FDA-approved ADHD treatment INTUNIV; Vyvanse, the first prodrug stimulant for the treatment of ADHD; and Daytrana, the only patch approved for the treatment of ADHD. We are proud to provide important contributions to the growing body of research on our ADHD portfolio to the medical community."

SOURCE Shire plc

90dbfda0-42c4-4824-adbb-9725dc6d8df7|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Abdominal Pain, Allergy, Anxiety, Arteriosclerosis, Bipolar Disorder, Blood Pressure, CDC, Constipation, Depression, Glaucoma, Hypersensitivity, Hyperthyroidism, Nausea, Pseudoephedrine, Psychiatry, Psychosis, Vomiting, Weight Loss

Related posts

Obama's budget demonstrates his strong commitment to end HIV"The budget President Obama outlined today yet again demonstrates his strong commitment to ending HI...
Matrix receives FDA's tentative approval for novel co-packaged version of HIV/AIDS therapyMylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative ap...
Tips for preventing heat-related illnessWith "feels-like" temperatures approaching or exceeding 100 degrees forecast for parts of Pennsylvan...
New findings from Deplin clinical trial on major depressive disorder presented at NCDEUNew findings from a multi-center, randomized, placebo-controlled clinical study of Deplin 15mg added...
Delayed treatment could prove effective in certain medical conditionsIn today's fast-paced world, waiting — whether it's at the doctor's office, in line at the grocery s...
FDA approves Novartis' Amturnide for treatment of high blood pressureToday Novartis announced that the US Food and Drug Administration (FDA) approved Amturnide (aliskire...
NHS Choices unveils typical signs, symptoms of cancerMore than 1/3 people in the UK will develop some form of cancer during their lifetime.The good news ...
Shire announces study results of Vyvanse Capsules CII for treatment of ADHD in adolescentsShire plc, the global specialty biopharmaceutical company, today announced the results of a study ev...
Lithera announces positive results from Phase IIa clinical study of LIPO-102Lithera, Inc. today announced positive results from a Phase IIa clinical study of LIPO-102, its nove...
Lysteda tablets to treat menorrhagia approved by the FDAThe U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first no...
Multi-state electronic tracking program to prevent diversion of common medicines for methamphetamine productionThe National Association of Drug Diversion Investigators (NADDI) today announced a new initiative in...
Study finds brain changes and severe depression in political detainees experiencing head injuryDepression and other emotional symptoms in survivors of torture and other traumatic experiences may ...
Want to shed more weight? Enroll a family member or friendEnrolling in a weight loss program with a family member or friend appears to enhance weight loss amo...
Advisory Committee on Immunization Practices supports the permissive use of GARDASILMerck & Co., Inc. announced today that the U.S. Centers for Disease Control and Prevention’s (CDC’s)...
Subject enrollment in patients with retinitis pigmentosa for Phase 2 clinical study completed by R-Tech UenoWe are pleased to announce that subject enrollment for the phase 2 clinical study of 0.15% UF-021 (g...
Researchers uncover attack mechanism of illness-inducing bacterium found in shellfishAn infectious ocean-dwelling bacterium found in oysters and other shellfish kills its host's cells b...
Anabolic steroids flip the adolescent brain's switch for aggressionAnabolic steroids not only make teens more aggressive, but may keep them that way into young adultho...
Texas Medication Algorithm Project guidelines produce improvements in patients with major depressive disorderResults from a multiyear study of severely depressed patients treated according to guidelines establ...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.